Ascendis Pharma A/S
ASND
34 hedge funds and large institutions have $646M invested in Ascendis Pharma A/S in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 7 reducing their positions, and 6 closing their positions.
114% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 7
10% more capital invested
Capital invested by funds: $585M → $646M (+$60.8M)
7.14% more ownership
Funds ownership: 64.46% → 71.6% (+7.1%)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
3% less funds holding
Funds holding: 35 → 34 (-1)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$17.2M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$14.7M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$12.1M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$10.6M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$13.5M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.8M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.48M |
| 4 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$2.05M |
| 5 |
EU
Emory University
Atlanta,
Georgia
|
-$633K |
ASND Hedge Fund Activity: Q2 2017 in Review
34 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q2 2017, worth a combined $646M — up 10% from $585M a quarter earlier.
Fund positioning in ASND was balanced in Q2 2017: 6 funds opened new positions, 6 closed out, 15 added to existing stakes and 7 trimmed.
The largest buyer was OrbiMed, adding an estimated $17.2M. The largest seller was Deerfield Management, cutting an estimated $13.5M.
- 34 institutional investors held Ascendis Pharma A/S (ASND) as of Q2 2017, down from 35 in Q1 2017.
- Funds reported $646M of Ascendis Pharma A/S stock for Q2 2017, up 10% quarter-over-quarter.
- 6 funds opened new Ascendis Pharma A/S positions in Q2 2017 and 6 closed out, a net change of 0 holders.
- The largest Ascendis Pharma A/S buyer in Q2 2017 was OrbiMed, an estimated $17.2M added.
- The largest Ascendis Pharma A/S seller in Q2 2017 was Deerfield Management, an estimated $13.5M sold.
Based on aggregated 13F filings for Q2 2017.